MedPath

Tagged News

NIH Scientists Develop Novel Surgical Technique to Enhance Cell Therapy for Dry Age-Related Macular Degeneration

AI
  • NIH researchers have developed a new surgical technique that enables implantation of multiple tissue grafts in the retina, potentially expanding treatment options for dry AMD.
  • The innovative surgical clamp maintains eye pressure during sequential insertion of two tissue patches while minimizing surrounding tissue damage.
  • Animal studies demonstrated that retinal pigment epithelial cell grafts promoted photoreceptor survival and regenerated the choriocapillaris blood vessel network.
  • The findings build upon an ongoing first-in-human clinical trial of patient-derived RPE grafts for dry AMD treatment.

Bayer Launches Centafore: New Imaging Core Lab to Enhance Clinical Trial Imaging and SaMD Development

OncologyAI
  • Bayer has launched Centafore, an Imaging Contract Research Organization (iCRO) with over 25 years of experience supporting more than 200 clinical trials globally.
  • Centafore offers comprehensive imaging services spanning from early research through Phase IV trials and Software as a Medical Device development across multiple therapeutic areas including oncology, cardiovascular, and CNS.
  • The new imaging solution provider leverages an extensive network of imaging professionals across 50+ countries, aiming to enhance trial outcomes and support informed decision-making in drug development.

AstraZeneca and Aptar Digital Health Partner to Develop AI Algorithms for Early Detection of Chronic Kidney Disease

AI
  • AstraZeneca and Aptar Digital Health have entered a licensing agreement to develop AI-powered algorithms that can detect chronic kidney disease during routine eye examinations, potentially revolutionizing early diagnosis.
  • The technology aims to address a significant global health challenge, as chronic kidney disease affects 8-16% of the global population but often remains undiagnosed until advanced stages.
  • Once developed, the AI solution will undergo clinical evaluation before being deployed through pharmaceutical companies, ophthalmic equipment manufacturers, and healthcare systems.

FDA Clears Ascletis' IND for ASC50, a Novel Oral IL-17 Inhibitor for Psoriasis Treatment

AI
  • The U.S. FDA has cleared Ascletis Pharma's IND application for ASC50, an oral small molecule IL-17 inhibitor, allowing Phase I trials in mild-to-moderate plaque psoriasis patients to begin in Q3 2025.
  • Preclinical data shows ASC50 demonstrates superior pharmacokinetics with higher drug exposure, longer half-life, and lower clearance compared to other oral IL-17 inhibitors in development, positioning it as a potential best-in-class treatment.
  • ASC50 represents Ascletis' first immunology candidate developed using their Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) Platform, marking a significant milestone in their autoimmune disease portfolio.

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

NCT07024602RecruitingPhase 1
Ascletis Pharma (China) Co., Limited
Posted 6/1/2025

Viz.ai Partners with Sanofi and Regeneron to Deploy AI-Powered COPD Management Solution

AI
  • Viz.ai has entered a multi-year collaboration with Sanofi and Regeneron to deploy and evaluate an AI-powered workflow solution for chronic obstructive pulmonary disease management.
  • The Viz COPD module will leverage electronic health record data and natural language processing to identify and triage high-risk COPD patients according to established clinical guidelines.
  • The collaboration addresses significant unmet needs in COPD care, targeting a disease that affects 392 million people globally and represents the fourth leading cause of death worldwide.
  • The AI solution builds upon Viz.ai's existing presence across over 1,700 hospitals and health systems, engaging more than 60,000 healthcare providers to enhance respiratory care coordination.

New AI Blood Test ARTEMIS-DELFI Shows Promise for Monitoring Pancreatic Cancer Treatment Response

AIOncology
  • Johns Hopkins researchers have developed ARTEMIS-DELFI, an AI-powered blood test that detects tumor DNA fragments to monitor pancreatic cancer treatment response more effectively than traditional imaging methods.
  • The new technique outperformed conventional methods in two clinical trials, identifying patient responses as early as four weeks after treatment initiation, potentially allowing for faster therapy adjustments.
  • ARTEMIS-DELFI offers significant advantages over other approaches as it doesn't require tumor samples, works with more patients, and provides a simpler, potentially less expensive monitoring solution for pancreatic cancer patients.

Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients

NCT02767557CompletedPhase 2
Herlev Hospital
Posted 1/26/2017

Immune Checkpoint Inhibition in Combination With Radiation Therapy in Pancreatic Cancer or Biliary Tract Cancer Patients

NCT02866383CompletedPhase 2
Herlev Hospital
Posted 11/1/2016

ONWARD Medical Advances Brain-Computer Interface Technology with Fifth Successful Implant for Spinal Cord Injury Patients

AINeurology
  • ONWARD Medical has successfully implanted its ARC-BCI® Therapy in two additional patients, bringing the total to five individuals with spinal cord injuries who can now potentially control movement through thought.
  • The innovative DigitalBridge™ system creates a wireless connection between brain and spinal cord, using AI to decode neural signals and translate intention into movement, bypassing damaged neural pathways.
  • With FDA Breakthrough Device Designation and growing clinical evidence, ONWARD's less invasive BCI approach is positioning the company as a leader in neurotechnology for restoring function after paralysis.

NIH-Funded Teams Develop Precision Gene Delivery Systems for Neural Cells

Precision MedicineAI
  • Research teams funded by the NIH have created a versatile toolkit of gene delivery systems that can target specific neural cell types in the human brain and spinal cord with unprecedented precision.
  • The new delivery platform uses modified adeno-associated viruses (AAVs) to transport genetic material into targeted cells, potentially transforming how scientists study neural circuits without requiring genetically modified animals.
  • This breakthrough could accelerate the development of precise gene therapies for neurological disorders like ALS, Alzheimer's, and Parkinson's disease by targeting only affected cells rather than merely treating symptoms.

Basil Systems Secures $11.5M to Revolutionize Life Sciences Decision-Making with AI

AIReal World Evidence
• Basil Systems has raised $11.5 million in funding led by Golden Ventures, with participation from Hearst Ventures and Argosy Capital, to expand its AI-powered product lifecycle intelligence platform.
• The company has built BasilLink, the largest indexed dataset in life sciences with over 600 million records, providing real-time insights for regulatory submissions, clinical planning, and post-market surveillance.
• Already utilized by four of the five largest global medical device companies and in trials with major pharmaceutical firms, Basil's platform aims to transform fragmented regulatory and clinical data into actionable intelligence.

Synfini and Multispan Partner to Accelerate GPCR Drug Discovery Using AI and Automation

AIDrug Discovery
  • Synfini, Inc. and Multispan have formed a strategic collaboration to co-discover and develop drug candidates targeting an undisclosed G protein-coupled receptor (GPCR), combining AI-driven chemistry with specialized GPCR biology expertise.
  • The partnership leverages Synfini's AI Cloud Foundry platform to accelerate "design-make-test-analyze" cycles in molecular discovery, with early collaboration milestones already achieved according to Multispan's CEO.
  • Beyond their initial target, the companies will make their combined technology platforms commercially available as a "one-stop shop" for accelerated drug discovery, offering AI, automation, and cutting-edge biology services to external clients.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.